Cargando…
The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
BACKGROUND: Epigenetic control using histone deacetylase (HDAC) inhibitors is a promising therapy for lymphomas. Insights into the anti-proliferative effects of HDAC inhibitors on diffuse large B-cell lymphoma (DLBCL) and further understanding of the underlying mechanisms, which remain unclear to da...
Autores principales: | Cai, Ying, Cui, Wenli, Chen, Weixiang, Wei, Ping, Chi, Yayun, Zhang, Ping, Bi, Rui, Zhou, Xiaoyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681717/ https://www.ncbi.nlm.nih.gov/pubmed/23758695 http://dx.doi.org/10.1186/1475-2867-13-57 |
Ejemplares similares
-
Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014) -
The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines
por: de Andrade, Pamela Viani, et al.
Publicado: (2016) -
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006) -
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
por: Weberpals, Johanne I, et al.
Publicado: (2011) -
Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
por: Hurtubise, Annie, et al.
Publicado: (2008)